北京大学学报(医学版) ›› 2022, Vol. 54 ›› Issue (4): 628-635. doi: 10.19723/j.issn.1671-167X.2022.04.008

• 论著 • 上一篇    下一篇

成纤维细胞生长因子受体2在肾透明细胞癌中的表达及意义

蔡天玉,朱振鹏,徐纯如,吉星,吕同德,郭振可,林健*()   

  1. 北京大学第一医院泌尿外科,北京大学泌尿外科研究所,国家泌尿男生殖系肿瘤研究中心,北京 100034
  • 收稿日期:2022-04-05 出版日期:2022-08-18 发布日期:2022-08-11
  • 通讯作者: 林健 E-mail:linjianbj@163.com
  • 基金资助:
    国家自然科学基金(82070704)

Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma

Tian-yu CAI,Zhen-peng ZHU,Chun-ru XU,Xing JI,Tong-de LV,Zhen-ke GUO,Jian LIN*()   

  1. Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; National Urological Can-cer Center, Beijing 100034, China
  • Received:2022-04-05 Online:2022-08-18 Published:2022-08-11
  • Contact: Jian LIN E-mail:linjianbj@163.com
  • Supported by:
    the National Natural Science Foundation of China(82070704)

摘要:

目的: 研究成纤维细胞生长因子受体2(fibroblast growth factor receptor 2,FGFR2)在肾透明细胞癌(clear cell renal cell carcinoma,ccRCC;or kidney renal clear cell carcinoma,KIRC)中的表达情况,对FGFR2的表达与ccRCC临床病理特征及预后关系进行分析,并研究FGFR2的表达与其他分子之间作用关系,探讨其在ccRCC发生发展中的作用。方法: 从肿瘤基因图谱(The Cancer Genome Atlas, TCGA)数据库及基因表达综合(Gene Expression Omnibus,GEO)数据库中下载ccRCC患者的基因表达及临床信息资料,进行转化及整理,并收集北京大学第一医院泌尿外科104例临床ccRCC样本及癌旁正常组织样本,进行免疫组织化学染色(immunohistochemistry, IHC),对染色结果进行评分,从而比较ccRCC和癌旁正常组织中FGFR2的蛋白表达情况;采用实时荧光定量聚合酶链反应(quantify real-time polymerase chain reaction,qRT-PCR)检测正常的肾上皮细胞系(293)和肾细胞癌细胞系(786-O、769-P、OSRC-2、Caki-1、ACHN、A498)中FGFR2的mRNA表达水平;对数据库中的ccRCC患者进行进一步分析,研究FGFR2表达与ccRCC患者临床病理特征(包括TNM分期和病理分级)以及生存预后的关系,分析ccRCC患者中FGFR2表达与B细胞、T细胞、自然杀伤(natural killer,NK)细胞及中性粒细胞浸润的关系,并使用生物交互数据集通用存储库(Biological General Repository for Interactionh Datasets,BioGRID)构建蛋白质相互作用(protein-protein interaction,PPI)网络,利用网络研究与FGFR2蛋白相互作用的分子。结果: 在TCGA数据库中,相较于正常组织样本,FGFR2在ccRCC组织样本中表达下调,在GEO数据库中的表达也呈现出这一差异,并且FGFR2在ccRCC临床样本及ccRCC细胞系中表达下调,此外,FGFR2表达水平与ccRCC高分级分期相关,与ccRCC患者较好的预后相关,并且FGFR2表达与B细胞、T细胞、NK细胞及中性粒细胞浸润无明显相关关系。PPI网络显示FGFR2蛋白与某些分子间存在相互作用。结论: 本研究揭示了FGFR2与ccRCC发生发展的潜在作用关系,提示FGFR2可能作为ccRCC患者的预后标志物和潜在治疗靶点。

关键词: 成纤维细胞生长因子受体2, 肾透明细胞癌, 生物标志物

Abstract:

Objective: To investigate the expression of fibroblast growth factor receptor 2 (FGFR2) in clear cell renal cell carcinoma (ccRCC; or kidney renal clear cell carcinoma, KIRC), to analyze the relationship between the expression of FGFR2 and the clinical pathological features and prognosis of ccRCC, to study the relationship between the expression of FGFR2 and other molecules, and to explore its role in the development of ccRCC. Methods: Gene expressional and clinical information of ccRCC patients were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus(GEO) database. Next, the data were transformed and collated. In the study, 104 clinical ccRCC samples and corresponding paracancerous normal tissue samples were collected from Department of Urology, Peking University First Hospital. Immunohistochemistry (IHC) was performed and the staining results were scored, so as to compare the expression of FGFR2 in ccRCC and paracancerous normal tissues. Besides, quantify real-time polymerase chain reaction (qRT-PCR) was used to detect the mRNA expression level of FGFR2 in normal renal epithelial cell lines (293) and ccRCC cell lines (786-O, 769-P, OSRC-2, Caki-1, ACHN, and A498). In addition, the relationship between FGFR2 expression and clinical pathological characteristics (including TNM staging and pathological grading) and survival prognosis in ccRCC patients was further analyzed. Furthermore, the relationship between FGFR2 expression and B cells, T cells, natural killer (NK) cells and neutrophil infiltration in the ccRCC patients was analyzed, and the Biological General Repository for Interactionh Datasets (BioGRID) was used to builds protein-protein interaction (PPI) networks to study molecules that interacted with the FGFR2 protein. Results: In the TCGA database, the expression of FGFR2 was down-regulated in ccRCC tissue samples compared with normal tissue samples, and the expression in the GEO database also showed this differences. Furthermore, FGFR2 expression was downregulated in ccRCC clinical samples and ccRCC cell lines, compared with corresponding paracancerous normal tissue or normal renal epithelial cell lines. In addition, FGFR2 high expression was associated with earlier, lower-level ccRCC and was associated with a better prognosis in the patients with ccRCC. Moreover, FGFR2 expression was not significantly related to B cells, T cells, NK cells and neutrophil infiltration, and the PPI network showed that FGFR2 protein interacted with certain molecules. Conclusion: Our work sheds light on the potential role of FGFR2 in the development of ccRCC, suggesting that FGFR2 may serve as a prognostic marker and potential therapeutic target for patients with ccRCC.

Key words: Fibroblast growth factor receptor 2, Clear cell renal cell carcinoma, Biomarker

中图分类号: 

  • R34

图1

TCGA数据库中ccRCC肿瘤样本及正常组织中的FGFR2 mRNA表达水平"

图2

GEO数据库中ccRCC肿瘤样本及正常组织中的FGFR2 mRNA表达水平"

图3

正常组织及ccRCC组织中FGFR2的免疫组织化学染色情况(IHC ×40)"

图4

正常细胞系(293)及RCC细胞系中FGFR2相对mRNA表达量"

表1

TCGA数据库中ccRCC患者的基线资料"

Items Low expression of FGFR2(n=269) High expression of FGFR2(n =270) P
T stage, n (%) 0.001
    T1 117 (21.7) 161 (29.9)
    T2 46 (8.5) 25 (4.6)
    T3 100 (18.6) 79 (14.7)
    T4 6 (1.1) 5 (0.9)
N stage, n (%) 1.000
    N0 128 (49.8) 113 (44.0)
    N1 9 (3.5) 7 (2.7)
M stage, n (%) 1.000
    M0 216 (42.7) 212 (41.9)
    M1 39 (7.7) 39 (7.7)
Pathologic stage, n (%) 0.002
    Stage Ⅰ 115 (21.5) 157 (29.3)
    Stage Ⅱ 36 (6.7) 23 (4.3)
    Stage Ⅲ 74 (13.8) 49 (9.1)
    Stage Ⅳ 42 (7.8) 40 (7.5)
OS event, n (%) 0.009
    Alive 168 (31.2) 198 (36.7)
    Dead 101 (18.7) 72 (13.4)
Age, M (IQR) 61 (52, 70) 60 (51, 69) 0.241

图5

TCGA数据库中ccRCC患者FGFR2表达生存分析曲线及与肿瘤TNM分期、病理分级和OS的关系"

图6

ccRCC患者中FGFR2表达与B细胞、T细胞、NK细胞及中性粒细胞浸润情况"

图7

FGFR2的蛋白相互作用网络"

1 Cohen HT . Renal-cell carcinoma[J]. N Engl J Med, 2005, 353 (23): 2477- 2490.
doi: 10.1056/NEJMra043172
2 Siegel RL , Miller KD , Fuchs HE , et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71 (1): 7- 33.
doi: 10.3322/caac.21654
3 Hsieh JJ , Purdue MP , Signoretti S , et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3 (1): 17009.
doi: 10.1038/nrdp.2017.9
4 Rini BI , Campbell SC , Escudier B . Renal cell carcinoma[J]. Lancet, 2009, 373 (9669): 1119- 1132.
doi: 10.1016/S0140-6736(09)60229-4
5 Penticuff JC , Kyprianou N . Therapeutic challenges in renal cell carcinoma[J]. Am J Clin Exp Urol, 2015, 3 (2): 77- 90.
6 Wolff I , May M , Hoschke B , et al. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database[J]. Eur J Surg Oncol, 2016, 42 (5): 744- 750.
doi: 10.1016/j.ejso.2016.01.009
7 Williamson TJ , Pearson JR , Ischia J , et al. Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma[J]. BJU Int, 2016, 117 (4): 555- 562.
doi: 10.1111/bju.13384
8 Eswarakumar VP , Lax I , Schlessinger J . Cellular signaling by fibroblast growth factor receptors[J]. Cytokine Growth Factor Rev, 2005, 16 (2): 139- 149.
doi: 10.1016/j.cytogfr.2005.01.001
9 Li P , Huang T , Zou Q , et al. FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK/STAT3 signaling pathway[J]. J Immunol, 2019, 202 (10): 3065- 3075.
doi: 10.4049/jimmunol.1801199
10 Wang Y , Shi T , Wang X , et al. FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma[J]. J Transl Med, 2021, 19 (1): 1- 11.
doi: 10.1186/s12967-020-02683-4
11 Oughtred R , Rust J , Chang C , et al. The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions[J]. Protein Sci, 2021, 30 (1): 187- 200.
doi: 10.1002/pro.3978
12 Siegel RL , Miller KD , Jemal A . Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70 (1): 7- 30.
doi: 10.3322/caac.21590
13 Turner N , Grose R . Fibroblast growth factor signalling: from development to cancer[J]. Nat Rev Cancer, 2010, 10 (2): 116- 129.
14 Zhang J , Wong CC , Leung KT , et al. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinoge-nesis in a subgroup of gastric cancer patients and indicates translational potential[J]. Oncogene, 2020, 39 (43): 6647- 6663.
doi: 10.1038/s41388-020-01458-x
15 Huang T , Liu D , Wang Y , et al. FGFR2 Promotes gastric cancer progression by inhibiting the expression of thrombospondin4 via PI3K-Akt-Mtor pathway[J]. Cell Physiol Biochem, 2018, 50 (4): 1332- 1345.
doi: 10.1159/000494590
16 Lei JH , Lee MH , Miao K , et al. Activation of FGFR2 signaling suppresses BRCA1 and drives triple-negative mammary tumorigenesis that is sensitive to immunotherapy[J]. Adv Sci, 2021, 8 (21): e2100974.
doi: 10.1002/advs.202100974
17 Goyal L , Shi L , Liu LY , et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma[J]. Cancer Discov, 2019, 9 (8): 1064- 1079.
18 Lee JE , Shin SH , Shin HW , et al. Nuclear FGFR2 negatively regulates hypoxia-induced cell invasion in prostate cancer by interacting with HIF-1 and HIF-2[J]. Sci Rep, 2019, 9 (1): 3480.
doi: 10.1038/s41598-019-39843-6
19 Volkova M , Tsimafeyeu I , Olshanskaya A , et al. Immunochemical expression of fibroblast growth factor and its receptors in primary tumor cells of renal cell carcinoma[J]. Am J Clin Exp Urol, 2021, 9 (1): 65- 72.
20 Zhao Q , Caballero OL , Davis ID , et al. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas[J]. Clin Cancer Res, 2013, 19 (9): 2460- 2472.
21 Ranieri D , Nanni M , Guttieri L , et al. The aberrant expression in epithelial cells of the mesenchymal isoform of FGFR2 controls the negative crosstalk between EMT and autophagy[J]. J Cell Mol Med, 2021, 25 (8): 4166- 4172.
[1] 张波. 弥漫性神经内分泌细胞肿瘤病理学:共性与异质性[J]. 北京大学学报(医学版), 2023, 55(2): 210-216.
[2] 曹芳,钟明,刘从容. 宫体POLE突变型内膜样癌合并HPV感染相关性宫颈腺癌1例报道及文献回顾[J]. 北京大学学报(医学版), 2023, 55(2): 370-374.
[3] 梁丽,李鑫,农琳,董颖,张继新,李东,李挺. 子宫内膜癌微卫星不稳定性分析: 微小微卫星变换的意义[J]. 北京大学学报(医学版), 2023, 55(2): 254-261.
[4] 柯杨,王敏敏,刘萌飞,刘芳芳,刘英,何忠虎. 肿瘤早期预警生物标志物的研究与思考[J]. 北京大学学报(医学版), 2022, 54(5): 810-813.
[5] 左美妮,杜依青,于路平,戴翔,徐涛. 代谢综合征与肾透明细胞癌患者预后的相关性[J]. 北京大学学报(医学版), 2022, 54(4): 636-643.
[6] 陈怀安,刘硕,李秀君,王哲,张潮,李凤岐,苗文隆. 炎症生物标志物对输尿管尿路上皮癌患者预后预测的临床价值[J]. 北京大学学报(医学版), 2021, 53(2): 302-307.
[7] 杨飞龙,洪锴,赵国江,刘承,宋一萌,马潞林. 基于长链非编码RNA的生物信息学分析构建膀胱癌预后模型并确定预后生物标志物[J]. 北京大学学报(医学版), 2019, 51(4): 615-622.
[8] 贺大林,徐珊,郭鹏. 外泌体在泌尿系肿瘤精准诊断中的应用[J]. 北京大学学报(医学版), 2017, 49(4): 561-564.
[9] 刘瑾,熊耕砚,唐琦,方冬,李学松,周利群. 上尿路尿路上皮癌中RASSF1A基因启动子区域的甲基化状态及其临床意义[J]. 北京大学学报(医学版), 2016, 48(4): 571-578.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 柳晓辉, 那加, 刘玲玲, 罗斌. 头颈部血管肉瘤3例[J]. 北京大学学报(医学版), 2001, 33(3): 288 -289 .
[2] 呼群, 宁涛, 苏秀兰, 王文礼, 柯杨. 鸡胚绒毛尿囊膜技术的改进[J]. 北京大学学报(医学版), 2001, 33(4): 383 -385 .
[3] 陈倩, 郭燕燕. 妊娠合并慢性肾炎19例临床分析及随访[J]. 北京大学学报(医学版), 2002, 34(1): 93 -94 .
[4] 张震康. 口腔医学科学研究的重要进展和方向[J]. 北京大学学报(医学版), 2002, 34(2): 97 -98 .
[5] 郭应禄, 张凯. 临床研究所要创高水平医疗[J]. 北京大学学报(医学版), 2002, 34(5): 431 -433 .
[6] 方鹏骞, 徐娟, 张佳慧, 李翠, 杨芳, 孔鹏, 孙杨. 艾滋病高危人群规模间接估计方法的应用及其结果的外推研究[J]. 北京大学学报(医学版), 2008, 40(2): 214 -218 .
[7] 张勇, 栾庆先. 牙周维护治疗在保持牙周长期疗效中的作用[J]. 北京大学学报(医学版), 2011, 43(1): 29 -33 .
[8] 孙宇, 刘毅强, 冯国双, 李吉友. 转化生长因子β1在萎缩性胃炎发生中的作用[J]. 北京大学学报(医学版), 2009, 41(6): 635 -639 .
[9] 张少衡, 贾竹青, 郭静萱, 张萍, 马康涛, 王淑玲, 刘永刚, 李凌松, 周春燕. 骨髓细胞移植上调血管内皮生长因子及其受体的表达并改善缺血心脏功能[J]. 北京大学学报(医学版), 2003, 35(4): 429 -433 .
[10] 辛岗, 赵明辉, 丁焦生, 王海燕. 牛肾小球基底膜Ⅳ型胶原α链非胶原区1的分离纯化及其在抗肾小球基底膜相关疾病中的应用[J]. 北京大学学报(医学版), 2003, 35(5): 494 -498 .